Abstract
Introduction: Approximately 15% of breast cancer patients present with large tumors that involve the skin, the chest wall, or the regional lymph nodes. Multimodality therapy is required, to provide the best chance for long-term survival. We have developed a regimen of paclitaxel, with concomitant radiation, as a primary therapy in patients with locally advanced breast cancer.
Methods: Eligible patients had locally advanced breast cancer (stage IIB or III). After obtaining informed consent, patients received paclitaxel (30 mg/m2 during 1 hour) twice per week for 8 weeks and radiotherapy to 45 Gy (25 fractions, at 180 cGy/fraction, to the breast and regional nodes). Patients then underwent modified radical mastectomy followed by postoperative polychemotherapy.
Results: Twenty-nine patients were enrolled. Of these, 28 were assessable for clinical response and toxicity, and 27 were assessable for pathological response. Objective clinical response was achieved in 89%. At the time of surgery, 33% had no or minimal microscopic residual disease. Chemoradiation-related acute toxicity was limited; however, surgical complications occurred in 41% of patients.
Conclusions: Preoperative paclitaxel with radiotherapy is well tolerated and provides significant pathological response, in up to 33% of patients with locally advanced breast cancer, but with a significant postoperative morbidity rate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lippman ME, Sorace RA, Bagley CS, et al. Treatment of Locally Advanced Breast Cancer Using Primary Induction Chemotherapy With or Without Debulking Surgery, vol 1. NCI Monograph, 1986:153–159.
Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889–3894.
Hortobagyi GN, Buzdar AU. Locally advanced breast cancer: a review including the M. D. Anderson experience. In: Ragaz J, Ariel IM, eds. High-Risk Breast Cancer Therapy. Berlin: Springer-Verlag, 1991:382–415.
Holmes F, Valero V, Walters J, et al. The MD Anderson Cancer Center Experience with Taxol and Metastatic Breast Cancer, vol 15. NCI Monograph, 1993:161–169.
Seidman A, Reichman B, Crown J, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;3:1152–1159.
Nabholtz J, Gelmon K, Bontenbal M, et al. Randomized trial of two doses of paclitaxel in metastatic breast cancer. J Clin Oncol 1996;14:1858–1867.
Wilson W, Berg S, Kang Y, et al. Phase I/II study of 96-hour infusion in refractory lymphoma and breast cancer. J Clin Oncol 1996;14:1858–1867. 51:763–768.
Mamounas E, Brown A, Fisher B, et al. Three hour, high-dose taxol infusion in advanced breast cancer (ABC): an NSABP phase II study (abstract). Proc Am Soc Clin Oncol 1995;15:127.
Abrams J, Vena D, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Referral Center Trial. J Clin Oncol 1995;13:2056–2065.
Bishop J, Dewar J, Toner G, et al. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. Semin Oncol 1997;24(Suppl 17):S17-5–S17-9.
Buzdar A, Hortobagyi G, Asmar L, et al. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol 1997;25(Suppl 17):S17-31–S17-34.
Formenti SC, Fraser S, Volm M, et al. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 1999;9(Suppl 1):34–42.
Formenti SC, Danenberg PV. Paclitaxel-induced radiosensitization: myth or reality? Adv Oncol 1999;5:25–29.
Formenti SC, Skinner KA, Spicer D, et al. Paclitaxel with concomitant radiation therapy in locally advanced breast cancer (LABC): clinical and pathological response. J Clin Oncol (in press).
Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539–1545.
Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast Cancer. Cancer 1983;51:763–768.
Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73:362–369.
Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992;69:2849 –2852.
Eltahir A, Heys SD, Hutcheon AW, et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998;175:127–132.
Skinner KA, Dunnington G, Silberman H, et al. Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer. Am J Surg 1997;174:705–708.
Donaldson S, Glick J, Wilbur J. Adriamycin activating a recall phenomenon after radiation therapy. Int J Radiat Oncol Biol Phys 1974;81:407–408.
Richardson D, Johnson S. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 1997;11:201–223.
Bokemyer C, Lampe C, Heneka M, et al. Paclitaxel-induced radiation recall dermatitis. Ann Oncol 1996;7:755–756.
McCarty M, Peake M, Lillis P, Vukelja S. Paclitaxel-induced radiation recall dermatitis. Med Pediatr Oncol 1996;27:185–186.
Raghavan V, Bloomer W, Merkel D. Taxol and radiation recall dermatitis (letter). Lancet 1993;341:1354.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Skinner, K.A., Silberman, H., Florentine, B. et al. Preoperative Paclitaxel and Radiotherapy for Locally Advanced Breast Cancer: Surgical Aspects. Ann Surg Oncol 7, 145–149 (2000). https://doi.org/10.1007/s10434-000-0145-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0145-3